134 related articles for article (PubMed ID: 23857311)
1. α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans.
Hysek CM; Fink AE; Simmler LD; Donzelli M; Grouzmann E; Liechti ME
J Clin Psychopharmacol; 2013 Oct; 33(5):658-66. PubMed ID: 23857311
[TBL] [Abstract][Full Text] [Related]
2. Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers.
Hysek CM; Brugger R; Simmler LD; Bruggisser M; Donzelli M; Grouzmann E; Hoener MC; Liechti ME
J Pharmacol Exp Ther; 2012 Feb; 340(2):286-94. PubMed ID: 22034656
[TBL] [Abstract][Full Text] [Related]
3. Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects.
Schmid Y; Rickli A; Schaffner A; Duthaler U; Grouzmann E; Hysek CM; Liechti ME
J Pharmacol Exp Ther; 2015 Apr; 353(1):102-11. PubMed ID: 25655950
[TBL] [Abstract][Full Text] [Related]
4. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans.
Hysek CM; Simmler LD; Ineichen M; Grouzmann E; Hoener MC; Brenneisen R; Huwyler J; Liechti ME
Clin Pharmacol Ther; 2011 Aug; 90(2):246-55. PubMed ID: 21677639
[TBL] [Abstract][Full Text] [Related]
5. Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.
Hysek C; Schmid Y; Rickli A; Simmler LD; Donzelli M; Grouzmann E; Liechti ME
Br J Pharmacol; 2012 Aug; 166(8):2277-88. PubMed ID: 22404145
[TBL] [Abstract][Full Text] [Related]
6. Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex.
Hysek CM; Liechti ME
Psychopharmacology (Berl); 2012 Dec; 224(3):363-76. PubMed ID: 22700038
[TBL] [Abstract][Full Text] [Related]
7. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.
Liechti ME; Saur MR; Gamma A; Hell D; Vollenweider FX
Neuropsychopharmacology; 2000 Oct; 23(4):396-404. PubMed ID: 10989266
[TBL] [Abstract][Full Text] [Related]
8. Ethanol co-administration moderates 3,4-methylenedioxymethamphetamine effects on human physiology.
Dumont GJ; Kramers C; Sweep FC; Willemsen JJ; Touw DJ; Schoemaker RC; van Gerven JM; Buitelaar JK; Verkes RJ
J Psychopharmacol; 2010 Feb; 24(2):165-74. PubMed ID: 19074534
[TBL] [Abstract][Full Text] [Related]
9. Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy).
Hysek CM; Vollenweider FX; Liechti ME
Emerg Med J; 2010 Aug; 27(8):586-9. PubMed ID: 20378736
[TBL] [Abstract][Full Text] [Related]
10. Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthetized rat.
McDaid J; Docherty JR
Br J Pharmacol; 2001 Jun; 133(3):429-37. PubMed ID: 11375260
[TBL] [Abstract][Full Text] [Related]
11. Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans.
Dumont GJ; Kramers C; Sweep FC; Touw DJ; van Hasselt JG; de Kam M; van Gerven JM; Buitelaar JK; Verkes RJ
Clin Pharmacol Ther; 2009 Aug; 86(2):160-6. PubMed ID: 19440186
[TBL] [Abstract][Full Text] [Related]
12. Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans.
Liechti ME; Vollenweider FX
Eur Neuropsychopharmacol; 2000 Jul; 10(4):289-95. PubMed ID: 10871712
[TBL] [Abstract][Full Text] [Related]
13. No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA.
Vizeli P; Meyer Zu Schwabedissen HE; Liechti ME
Eur J Clin Pharmacol; 2018 Mar; 74(3):275-283. PubMed ID: 29198060
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.
Farré M; Abanades S; Roset PN; Peiró AM; Torrens M; O'Mathúna B; Segura M; de la Torre R
J Pharmacol Exp Ther; 2007 Dec; 323(3):954-62. PubMed ID: 17890444
[TBL] [Abstract][Full Text] [Related]
15. Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers.
Dumont GJ; Schoemaker RC; Touw DJ; Sweep FC; Buitelaar JK; van Gerven JM; Verkes RJ
J Psychopharmacol; 2010 Feb; 24(2):155-64. PubMed ID: 19164498
[TBL] [Abstract][Full Text] [Related]
16. Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart.
Farré M; Tomillero A; Pérez-Mañá C; Yubero S; Papaseit E; Roset PN; Pujadas M; Torrens M; Camí J; de la Torre R
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1637-49. PubMed ID: 26073279
[TBL] [Abstract][Full Text] [Related]
17. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.
Freedman RR; Johanson CE; Tancer ME
Psychopharmacology (Berl); 2005 Dec; 183(2):248-56. PubMed ID: 16163516
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination.
Hysek CM; Simmler LD; Schillinger N; Meyer N; Schmid Y; Donzelli M; Grouzmann E; Liechti ME
Int J Neuropsychopharmacol; 2014 Mar; 17(3):371-81. PubMed ID: 24103254
[TBL] [Abstract][Full Text] [Related]
19. Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart.
Peiró AM; Farré M; Roset PN; Carbó M; Pujadas M; Torrens M; Camí J; de la Torre R
Psychopharmacology (Berl); 2013 Feb; 225(4):883-93. PubMed ID: 23142957
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.
Mas M; Farré M; de la Torre R; Roset PN; Ortuño J; Segura J; Camí J
J Pharmacol Exp Ther; 1999 Jul; 290(1):136-45. PubMed ID: 10381769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
